JPH0731196B2 - Cell identification method in complex antigen-antibody reaction system and cell immobilization apparatus used in this method - Google Patents
Cell identification method in complex antigen-antibody reaction system and cell immobilization apparatus used in this methodInfo
- Publication number
- JPH0731196B2 JPH0731196B2 JP1075769A JP7576989A JPH0731196B2 JP H0731196 B2 JPH0731196 B2 JP H0731196B2 JP 1075769 A JP1075769 A JP 1075769A JP 7576989 A JP7576989 A JP 7576989A JP H0731196 B2 JPH0731196 B2 JP H0731196B2
- Authority
- JP
- Japan
- Prior art keywords
- liquid
- container
- antibody
- antigen
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims description 33
- 238000006243 chemical reaction Methods 0.000 title claims description 9
- 238000007444 cell Immobilization Methods 0.000 title claims 2
- 239000007788 liquid Substances 0.000 claims description 45
- 239000000126 substance Substances 0.000 claims description 22
- 239000000427 antigen Substances 0.000 claims description 15
- 102000036639 antigens Human genes 0.000 claims description 15
- 108091007433 antigens Proteins 0.000 claims description 15
- 108060003951 Immunoglobulin Proteins 0.000 claims description 14
- 102000018358 immunoglobulin Human genes 0.000 claims description 14
- 230000005484 gravity Effects 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 description 29
- 210000004698 lymphocyte Anatomy 0.000 description 26
- 210000003719 b-lymphocyte Anatomy 0.000 description 10
- 101710176108 Protein A30 Proteins 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 6
- 239000000306 component Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 4
- 238000013459 approach Methods 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 206010029719 Nonspecific reaction Diseases 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 230000024203 complement activation Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000000951 immunodiffusion Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000003544 deproteinization Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000004848 nephelometry Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5302—Apparatus specially adapted for immunological test procedures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
- G01N33/5375—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by changing the physical or chemical properties of the medium or immunochemicals, e.g. temperature, density, pH, partitioning
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/824—Immunological separation techniques
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Automatic Analysis And Handling Materials Therefor (AREA)
- Peptides Or Proteins (AREA)
Description
【発明の詳細な説明】 (産業上の利用分野) 本発明は様々な抗原を有する細胞や多種類の抗体を含む
液体の中から抗原と抗体が結合して成る抗原抗体複雑体
を有する細胞を同定する細胞同定法及びこの方法に使用
する装置に関する。DETAILED DESCRIPTION OF THE INVENTION (Industrial field of application) The present invention relates to cells having various antigens and cells having an antigen-antibody complex formed by combining antigens with antibodies from a liquid containing various kinds of antibodies. The present invention relates to a cell identification method for identification and an apparatus used for this method.
(従来の技術) 従来より一般に用いられている免疫反応検出方式には下
記のものがある。(Prior Art) Conventionally commonly used immune reaction detection methods are as follows.
沈降法、重層法、毛細管法、試験管法、免疫拡散法
等の特定的手法と、定量沈降法、レーザネフェロメトリ
ー、定量的免疫拡散法(SRID、RSRID、免疫電気拡散
法、交叉免疫電気泳動法)等の定量的手法がある。Specific methods such as sedimentation method, overlay method, capillary tube method, test tube method, immunodiffusion method, etc., quantitative precipitation method, laser nephelometry, quantitative immunodiffusion method (SRID, RSRID, immunoelectrodiffusion method, cross immunoelectricity method) There is a quantitative method such as electrophoresis.
溶血、溶菌法 凝集法;細胞凝集法、抗グロブリン試験(クームス
試験)、受身赤血球凝集法(PHA,HA)免疫粘着法(IA)
等がある。Hemolysis, lysis method Aggregation method; cell agglutination method, antiglobulin test (Cooms test), passive hemagglutination method (PHA, HA) immunoadhesion method (IA)
Etc.
受身皮膚アナフェラキシー法(PCA) 標識抗体法;免疫蛍光法(FIA)、酵素免疫法(EI
A)放射性同位元素標識法(RIA)等がある。Passive skin anaferax method (PCA) labeled antibody method; immunofluorescence method (FIA), enzyme immunoassay method (EI)
A) Radioisotope labeling method (RIA) is available.
(発明が解決しようとする課題) これらの各方法においては、用途により種々の改良が加
えられ、自動化、省略化が図られている。しかし一般的
な免疫反応においては特異性の高いモノクロナール抗体
ないし補体の存在しない場合あるいは補体が存在しても
補体活性機能が有効に使用しない場合が多い。このよう
な場合非特異反応その他の要因によるバックグラウンド
上昇が無視できない状態となり、目的とする特異反応の
同定が極めて困難となる。(Problems to be Solved by the Invention) In each of these methods, various improvements are added depending on the application, and automation and omission are achieved. However, in a general immune reaction, there are many cases where a highly specific monoclonal antibody or complement is not present, or the complement activating function is not effectively used even if complement is present. In such a case, the background rise due to nonspecific reaction and other factors cannot be ignored, and it becomes extremely difficult to identify the target specific reaction.
例えば溶皿、溶菌法に基づく組織適合性因子(HLA)の
細胞毒性試験(LCT)では次の様な問題点がある。この
試験は、多種、多様な特異性と抗体価を有する経産婦由
来の抗血清を抗体として用い、この抗体と検体リンパ球
表面HLA抗原と反応させてリンパ球を同定するものであ
る。この場合、反応の結果生じた抗原抗体複合体の影響
で特異的にリンパ球細胞膜損傷機能が高まる補体と、破
壊されたリンパ球を染める色素とが用いられる。そして
細胞損傷頻度に比例する色素染色度数からリンパ球の特
異性の高さが評価される。しかし、1のリンパ球の表面
において抗原が分散した状態等のように抗原濃度が薄い
状態にあるときは、補体活性能が充分に作用しない。ま
た、1gG4サブクラス抗体反応では補体活性能を認められ
ない。このような場合リンパ球の特異性の把握はきわめ
て困難となる。更に、HLA抗原は140種以上発見されてい
るが予測される抗原の種類は大巾にこの数を上まわる見
込であるにもかかわらず、固定の手段が確立されていな
い。For example, the cytotoxicity test (LCT) of histocompatibility factor (HLA) based on lysate and lysis method has the following problems. In this test, antiserum derived from a multiparous woman having various and various specificities and antibody titers is used as an antibody, and this antibody is reacted with a sample lymphocyte surface HLA antigen to identify lymphocytes. In this case, a complement that enhances the lymphocyte cell membrane damage function specifically under the influence of the antigen-antibody complex produced as a result of the reaction and a dye that stains the destroyed lymphocytes are used. Then, the degree of specificity of lymphocytes is evaluated from the degree of dye staining that is proportional to the frequency of cell damage. However, when the antigen concentration is low, such as the state where the antigen is dispersed on the surface of 1 lymphocyte, the complement activation ability does not sufficiently act. In addition, complement activation is not observed in the 1gG4 subclass antibody reaction. In such cases, it is extremely difficult to understand the specificity of lymphocytes. Furthermore, although more than 140 HLA antigens have been discovered, the types of predicted antigens are expected to greatly exceed this number, but means for immobilization have not been established.
本発明は補体を用いずに、かつ非特異反応を抑制してバ
ックグラウンドを低下させ、抗原抗体複合体を有する細
胞を同定することを目的とする。It is an object of the present invention to identify cells that have an antigen-antibody complex and suppress background by suppressing non-specific reaction without using complement.
[発明の構成] (課題を解決するための手段) 本発明の同定法は、妖気の内壁の一部に免疫グロブリン
と特異的に結合する物質を固着し、この容器に、抗原と
抗体が結合して成る抗原抗体複合体をその表面に有する
細胞を含む第1の液体よりも高比重の第2の液体を収容
してこの第2の液体に前記物質が浸漬された状態とし、
次にこの第2の液体の上に前記第1の液体を収容し、前
記内壁のうち、前記一部が最も回転中心から遠い位置と
なる状態で前記容器を回転運動させ、前記細胞を前記物
質に結合させて固相化した後、洗浄して同化するもので
ある。[Structure of the Invention] (Means for Solving the Problems) According to the identification method of the present invention, a substance that specifically binds to an immunoglobulin is fixed to a part of the inner wall of youkai, and an antigen and an antibody are bound to this container. A second liquid having a higher specific gravity than the first liquid containing cells having the antigen-antibody complex formed on the surface thereof is contained, and the substance is immersed in the second liquid,
Next, the first liquid is contained on the second liquid, and the container is rotatably moved in a state where the part of the inner wall is farthest from the rotation center, and the cells are treated with the substance. It is bound to and solidified to form a solid phase, which is then washed to assimilate.
本発明の装置は、容器と、この容器の内壁の一部に固着
され免疫グロブリンと特異的に結合する物質と、抗原と
抗体が結合して成る抗原抗体複合体を表面に有する細胞
を含む第1の液体よりも高比重であって前記物質を浸漬
するように前記容器に収容された第2の液体と、前記内
壁のうの前記一部が最も回転中心から遠い位置となる状
態で前記容器を回転運動させる容器回転手段とを具備す
るものである。The device of the present invention comprises a container, a substance fixed to a part of the inner wall of the container and specifically binding to an immunoglobulin, and a cell having an antigen-antibody complex formed by binding an antigen and an antibody on the surface thereof. The second liquid having a higher specific gravity than that of the first liquid and accommodated in the container so as to immerse the substance, and the container in a state where the part of the inner wall is located farthest from the center of rotation. And a container rotating means for rotating the container.
(作用) 本発明の同定法において、第1の液体中のある細胞はそ
の表面に抗原抗体複合体を有している。この複合体は細
胞の表面に存在する抗原とこの抗原に対する免疫グロブ
リン(抗体)が結合して成るものである。このような抗
原抗体複合体を有する細胞が第1の液体中に浮遊してい
る。次に容器を回転させたときに前記抗原抗体複合体を
有する細胞は遠心力を受け、前記第2の液体の中に入り
容器の内壁に固着された物質に近づく。そしてその物質
は前記細胞に結合している抗原抗体複合体を形成する免
疫グロブリンFC部と結合する。こうして前記細胞は容器
の内壁に固相化される。(Operation) In the identification method of the present invention, a cell in the first liquid has an antigen-antibody complex on its surface. This complex is composed of an antigen existing on the surface of a cell and an immunoglobulin (antibody) bound to this antigen. Cells having such an antigen-antibody complex are suspended in the first liquid. Next, when the container is rotated, the cells having the antigen-antibody complex are subjected to a centrifugal force, enter the second liquid, and approach the substance fixed to the inner wall of the container. The substance then binds to the immunoglobulin FC portion that forms the antigen-antibody complex bound to the cells. Thus, the cells are immobilized on the inner wall of the container.
ここで第1の液体に前記免疫グロブリン(免疫グロブリ
ン(I))とは異なる免疫グロブリン(II)、及び、前
記細胞(細胞(I))とは異なる細胞(II)が含まれて
おり、これらは相互に結合しないものとする。この場合
であっても前記内壁に固相化されるのは細胞(I)のみ
とすることができる。それは次の理由による。まず、免
疫グロブリン(II)は細胞(I)よりもきわめて小さい
ため拡散速度が遅い。このため細胞(I)の方が速く前
記物質に到達する。従って免疫グロブリン(II)が前記
物質に到達する前に容器の回転を止めるならば両者は区
別することができるからである。これは残余の免疫グロ
ブリン(I)であっても同様である。一方、細胞(II)
は、容器が回転すると遠心力により細胞(I)と同様に
前記物質に近づく。しかし細胞(II)は前記物質と結合
する免疫グロブリンを持たないため、単に前記物質及び
その周辺の容器内壁に当接するだけであり、洗浄される
ならば前記物質から容易に分離されるからである。Here, the first liquid contains immunoglobulin (II) different from the immunoglobulin (immunoglobulin (I)) and cells (II) different from the cells (cell (I)). Shall not be combined with each other. Even in this case, only cells (I) can be immobilized on the inner wall. The reason is as follows. First, since immunoglobulin (II) is much smaller than cells (I), its diffusion rate is slow. Therefore, the cell (I) reaches the substance faster. Therefore, the two can be distinguished from each other if the rotation of the container is stopped before the immunoglobulin (II) reaches the substance. The same applies to the remaining immunoglobulin (I). Meanwhile, cells (II)
When the container rotates, it approaches the substance like the cell (I) by the centrifugal force. However, since the cell (II) does not have an immunoglobulin that binds to the substance, it simply contacts the substance and the inner wall of the container around the substance, and is easily separated from the substance if washed. .
本発明に装置において、第1の液体と第2の液体とを容
器に収容し、この容器を容器回転手段によって回転させ
る。このとき抗原抗体複合体をその表面に有する細胞は
容器に固着されている物質に固相化される。この固相化
に至るまでの説明は、上記方法についての説明で既にな
されているのでここでは省略する。In the apparatus according to the present invention, the first liquid and the second liquid are contained in a container, and the container is rotated by the container rotating means. At this time, the cells having the antigen-antibody complex on their surface are immobilized on the substance fixed to the container. The description up to the solid phase has already been made in the description of the above method, and therefore will be omitted here.
(実施例) 本発明の同定方法の一実施例をその方法に用いられる装
置と共に説明する。(Example) An example of the identification method of the present invention will be described together with an apparatus used for the method.
第1図に本実施例装置の全体を示す。ドラム1は4本の
支持部材2を介して軸3に支持されている。軸3はその
両端を一対のアーム4に支持され回転自在とされてい
る。アーム4は、アーム支持台5により支持されてい
る。アーム支持台5は基台6に固定されている。アーム
支持台5は筐体であり、内部にモータが収容されてい
る。このモータの回転軸にギヤ7が取付けられている。
ドラム1の外周にはギヤ8が設けられており、このギヤ
8にギヤ7が噛み合っている。9はコントローラであ
る。コントローラ9は上記モータの回転速度を制御する
ものである。コントローラ9も基台6に取付けられてい
る。ドラム1の内壁には1個以上のホルダ10が隣接して
取付けられている。ホルダ10は第2図に示すようにウェ
ル11が多数個設けられたプレート12を着脱自在に保持す
るものである。第3図に示すように、各ウェル11にはそ
の底面内壁にプロティンA30が層状に固着されて固相さ
れている。FIG. 1 shows the entire apparatus of this embodiment. The drum 1 is supported by the shaft 3 via four support members 2. Both ends of the shaft 3 are supported by a pair of arms 4 and are rotatable. The arm 4 is supported by an arm support base 5. The arm support 5 is fixed to the base 6. The arm support 5 is a housing, and the motor is housed inside. A gear 7 is attached to the rotary shaft of this motor.
A gear 8 is provided on the outer periphery of the drum 1, and the gear 7 meshes with the gear 8. 9 is a controller. The controller 9 controls the rotation speed of the motor. The controller 9 is also attached to the base 6. One or more holders 10 are mounted adjacent to the inner wall of the drum 1. The holder 10 detachably holds a plate 12 having a large number of wells 11 as shown in FIG. As shown in FIG. 3, each well 11 has protein A30 fixed in layers on the inner wall of the bottom surface to be solid-phased.
本実施例では、血漿液に含まれている所定のリンパ球を
固相化するものである。従って第3図に示すように上記
所定のリンパ球より高比重の液体13がプレート12のウェ
ル11に収容されている。検査を受ける血漿液14は液体13
の上に保持されてい。血漿液14には、血清成分15、血球
成分16、A抗体17、B抗体18、Aリンパ球19及びBリン
パ球20が含まれている。ここで血清成分15と血球成分16
は免疫反応に直接関与しない血液成分である。A抗体17
及びAリンパ球19は免疫反応において非特異的であり、
B抗体18及びBリンパ球20は免疫反応において特異的で
ある。すなわちBリンパ球20はB抗体18の一部と抗原抗
体反応を生じ、B抗体18と結合する。この実施例では同
じリンパ球を含む血漿液を夫々各ウェル11に収容し、夫
々に異なる抗体を加え、抗原抗体反応が生じたリンパ球
を同化するものとする。1のプレート12には96個のウェ
ル11が設けられている。各プーレート12の各ウェル11が
第3図に示すように血漿液14より高比重の液体13と血漿
液14とを注入された状態とされている。この第3図に示
す状態から明らかなように操作者はウェル11にまず高比
重の液体13を注入し、次に血漿液14を注入する。このよ
うにしなければドラム1を回転させる前に血漿液14中の
抗体がウェル11に固相されたプロティンA30に捕捉され
るからである。操作者は1個以上のプレート12を第1図
に示すホルダ10に保持させコントローラ9を操作し、ド
ラム1を回転させる。コントローラ9は、ドラム1が第
1回転目から最終回転目に至るまでその回転速度を制御
してウェル11内の血漿液14と液体13との位置関係が維持
されるようにする。In this example, predetermined lymphocytes contained in plasma fluid are immobilized. Therefore, as shown in FIG. 3, the liquid 13 having a higher specific gravity than the predetermined lymphocytes is contained in the well 11 of the plate 12. Plasma liquid 14 to be tested is liquid 13
Is held on. The plasma liquid 14 contains serum component 15, blood cell component 16, A antibody 17, B antibody 18, A lymphocyte 19, and B lymphocyte 20. Here, serum component 15 and blood cell component 16
Is a blood component that is not directly involved in the immune response. A antibody 17
And A lymphocyte 19 are non-specific in the immune response,
B antibody 18 and B lymphocyte 20 are specific in the immune response. That is, the B lymphocyte 20 causes an antigen-antibody reaction with a part of the B antibody 18 and binds to the B antibody 18. In this example, plasma liquid containing the same lymphocytes is contained in each well 11, and different antibodies are added to each well 11 to assimilate the lymphocytes in which an antigen-antibody reaction has occurred. One plate 12 is provided with 96 wells 11. As shown in FIG. 3, each well 11 of each pool 12 is filled with a liquid 13 having a higher specific gravity than the plasma liquid 14 and the plasma liquid 14. As is apparent from the state shown in FIG. 3, the operator first injects the high specific gravity liquid 13 into the well 11 and then the plasma liquid 14. This is because unless this is done, the antibody in the plasma liquid 14 is captured by the protein A30 immobilized in the well 11 before the drum 1 is rotated. The operator holds one or more plates 12 in the holder 10 shown in FIG. 1 and operates the controller 9 to rotate the drum 1. The controller 9 controls the rotational speed of the drum 1 from the first rotation to the final rotation so that the positional relationship between the plasma liquid 14 and the liquid 13 in the well 11 is maintained.
ドラム1が回転中、ウェル11内は次のような現象が生じ
る。まずAリンパ球19と、リンパ球20は液体13を通過し
てプロティンA30に到達する状態となる。ここでAリン
パ球19はプロティンA30に単に接触しているだけである
が、Bリンパ球20はB抗体18が結合しておりこのB抗体
18のFC部がプロティンA30に結合している。一方、血清
成分15、血球成分16、A抗体17、B抗体18(Bリンパ球
20と結合しなかった残余分)はAリンパ球19及びBリン
パ球20よりも拡散速度が遅いので、あるいは比重が小さ
いのでAリンパ球19及びBリンパ球20がプロティンA30
に到達した時点では未だ液体13の上層部に滞留した状態
となっている。The following phenomenon occurs in the well 11 while the drum 1 is rotating. First, the A lymphocytes 19 and the lymphocytes 20 pass through the liquid 13 and reach the protein A30. Here, A lymphocyte 19 is only in contact with protein A30, but B lymphocyte 20 is bound with B antibody 18, and this B antibody is
18 FC parts are connected to Protein A30. On the other hand, serum component 15, blood cell component 16, A antibody 17, B antibody 18 (B lymphocyte
The residue that did not bind to 20 has a slower diffusion rate than A lymphocytes 19 and B lymphocytes 20 or has a lower specific gravity, so that A lymphocytes 19 and B lymphocytes 20 have protein A30.
By the time it reaches, the liquid 13 is still in the upper layer.
コントローラ9はドラム1を予めセットされた時間回転
させると、これを停止させる。操作者はプロティンA30
が固着されているウェル11から液体13及び血漿液14を除
去し、所定時間プレート12を静置する。このときウェル
11の底部周辺は第4図に示すようにBリンパ球20がB抗
体18を介してプロティンA30に捕捉されており、またA
リンパ球19がウェル11の底部に接触している。次に操作
者はウェル11の底部を洗浄してAリンパ球19を除去し、
Bリンパ球20を残すようにする。このようにしてBリン
パ球20は固相化かされる。When the controller 9 rotates the drum 1 for a preset time, it stops it. Operator is Protein A30
The liquid 13 and the plasma liquid 14 are removed from the well 11 to which is adhered, and the plate 12 is allowed to stand for a predetermined time. Well at this time
As shown in FIG. 4, B lymphocytes 20 are captured by protein A30 via B antibody 18 around the bottom of 11 and A
Lymphocytes 19 are in contact with the bottom of well 11. The operator then washed the bottom of well 11 to remove A lymphocytes 19,
Try to leave 20 B lymphocytes. In this way, the B lymphocyte 20 is immobilized.
本実施例によれば血漿液の中から確実に所定のリンパ球
を固相化することができ、またこの方法に使用した装置
によれば確実に所定のリンパ球を同定することができ
る。According to the present example, the predetermined lymphocytes can be solidly immobilized from the plasma liquid, and the apparatus used in this method can surely identify the predetermined lymphocytes.
本実施例では容器内壁の一部に固着された物質はプロテ
ィンAであるが、これは免疫グロブリンと特異的に結合
するものであれば他の物質、例えばプロティンGであっ
ても良い。In this embodiment, the substance adhered to a part of the inner wall of the container is protein A, but it may be another substance, for example protein G, as long as it specifically binds to immunoglobulin.
また本実施例では同化されるべき細胞はリンパ球である
が、これはABO型、MN型、Rh型のいずれかの抗原を有す
る赤血球、あるいは組織適合性因子HLA抗原を有する血
小板であっても良い。ただしこれらの細胞を固相化する
場合には予め血漿液の中からこれらの細胞よりも比重が
大きい細胞、例えばリンパ球等を取り除いておく必要が
ある。Further, in the present example, the cells to be assimilated are lymphocytes, which may be erythrocytes having any of the ABO type, MN type, and Rh type antigens, or platelets having the histocompatibility factor HLA antigen. good. However, when immobilizing these cells, it is necessary to remove cells having a greater specific gravity than these cells, such as lymphocytes, from the plasma solution in advance.
本実施例装置ではウェル11は円柱状で底部が半球状であ
るが、ウェル11形状は第5図(a)〜(i)に示される
ようにいかなる形状であっても良い。第5図中(a)は
円錐台状、(b)はその上下が反転した形状、、(c)
は半楕円体状、(d)は球状、(e)は円錐状、(f)
は先端部が楕円体となっている円錐状、(g)は円柱
状、(h)は角柱状、(i)は角錐状である。In the apparatus of this embodiment, the well 11 has a columnar shape and a semi-spherical bottom, but the shape of the well 11 may be any shape as shown in FIGS. 5 (a) to (i). In FIG. 5, (a) is a truncated cone shape, (b) is an inverted shape, (c)
Is semi-ellipsoidal, (d) is spherical, (e) is conical, (f)
Has a conical shape with an ellipsoidal tip, (g) has a cylindrical shape, (h) has a prismatic shape, and (i) has a pyramidal shape.
また本実施例装置ではプレート12は四角形の板状である
が、この形状は円形の板状、多角形の板状であっても良
い。また、これらのプレートを層状に重ねた状態のもの
でも良い。Further, although the plate 12 has a quadrangular plate shape in the apparatus of this embodiment, this shape may be a circular plate shape or a polygonal plate shape. Alternatively, these plates may be stacked in layers.
また本実施例装置ではドラム1は円筒状であったが、こ
れは第6図(a)に示すような多角形の筒状のものでも
良いし、同図(d)に示されるように同軸的に複数個の
ドラムを重ねても良い。更に第6図(b)、(c)に示
すように軸3から支持部材40を突設し、その先端側にプ
レート12を保持させるようにしても良い。Further, in the apparatus of this embodiment, the drum 1 has a cylindrical shape, but it may have a polygonal cylindrical shape as shown in FIG. 6 (a) or a coaxial shape as shown in FIG. 6 (d). Alternatively, a plurality of drums may be stacked. Further, as shown in FIGS. 6 (b) and 6 (c), a supporting member 40 may be provided so as to project from the shaft 3, and the plate 12 may be held on the tip side thereof.
本実施例装置ではプレート12を鉛直面に沿って円軌道が
描かれるように回転させたが、第7図(a)(b)のよ
うにプレート12を回転させても良い。第7図(a)は鉛
直方向に設けられた軸50に対し水平方向にアーム60が取
り付けられ、このアーム60の先端にプレート12を支持す
る支持台70が回動自在となるように取付けられたもので
ある。この場合、軸50が回転すると支持台70は遠心力を
受けて徐々に傾き、回転速度が高まると一点鎖線で示す
如くもとの状態から鉛直平面に沿って90°傾いた状態に
近づくようになる。この例によれば軸50を最初から急激
に回転させなくとも、第3図に示した液体13と血漿14の
位置関係は常に維持される。第7図(b)は同図(a)
に示した支持台70が水平面に対し傾斜した状態でアーム
60の先端に取付けられたものである。この場合も第7図
(a)の効果と略同様の効果が得られる。In the apparatus of this embodiment, the plate 12 was rotated so that a circular orbit was drawn along the vertical plane, but the plate 12 may be rotated as shown in FIGS. 7 (a) and 7 (b). In FIG. 7 (a), an arm 60 is attached horizontally to a shaft 50 provided in the vertical direction, and a support base 70 for supporting the plate 12 is attached to the tip of the arm 60 so as to be rotatable. It is a thing. In this case, when the shaft 50 rotates, the support base 70 receives the centrifugal force and gradually inclines, and when the rotation speed increases, the support base 70 approaches a state in which it is inclined by 90 ° along the vertical plane from the original state as shown by the alternate long and short dash line. Become. According to this example, the positional relationship between the liquid 13 and the plasma 14 shown in FIG. 3 is always maintained even if the shaft 50 is not rapidly rotated from the beginning. FIG. 7 (b) is the same figure (a).
Arm with the support 70 shown in Fig.
It is attached to the tip of 60. Also in this case, the same effect as the effect of FIG. 7 (a) can be obtained.
[発明の効果] 本発明によれば、補体を用いることなく、かつ非特異反
応を抑制しながら正確に細胞を同定することができる。
この場合、リンパ球単離、除蛋白、血清分離等の検体血
液の前処理を厳密に行う必要が無い。EFFECTS OF THE INVENTION According to the present invention, cells can be identified accurately without using complement and while suppressing non-specific reactions.
In this case, it is not necessary to strictly perform pretreatment of the sample blood such as lymphocyte isolation, deproteinization, and serum separation.
本発明によればリンパ球の損傷がほとんど無いので、本
発明を血液細胞学、免疫学研究における検体前処理に応
用できる。According to the present invention, since there is almost no damage to lymphocytes, the present invention can be applied to specimen pretreatment in hematology and immunology studies.
本発明において、第2の液体の組成及び比重を調整すれ
ば、本発明を血液成分の分離、濃縮、除去に応用するこ
とができる。In the present invention, by adjusting the composition and specific gravity of the second liquid, the present invention can be applied to separation, concentration and removal of blood components.
本発明によれば簡単な装置によって自動化することがで
きるので、コスト、時間、労力の削減を図ることができ
る。According to the present invention, since automation can be performed by a simple device, cost, time and labor can be reduced.
第1図は本発明方法に使用される装置の全体構成図、第
2図は第1図に示したプレートの拡大図、第3図は第1
図及び第2図に示したプレートのウェルに収容された液
体の説明図、第4図は第3図に示したウェル内の現象の
説明図、第5図は第3図に示したウェルの形状の他の例
を示す図、第6図は第1図に示したドラムに代わる種々
の構成を示す図、第7図は第1図に示したプレート12を
保持して回転させる機構の他の例を示す図である。 1…ドラム、2…支持部材 3…軸、4…アーム 5…アーム支持台、6…基台 7,8…ギア、9…コントローラ 11…ウェル、12…プレート 13…液体(第2の液体) 14…血漿液(第1の液体) 30…プロティンA1 is an overall configuration diagram of an apparatus used in the method of the present invention, FIG. 2 is an enlarged view of the plate shown in FIG. 1, and FIG.
And FIG. 2 are explanatory views of the liquid contained in the wells of the plate, FIG. 4 is an explanatory view of the phenomenon inside the well shown in FIG. 3, and FIG. 5 is a schematic view of the well shown in FIG. FIG. 6 is a view showing another example of the shape, FIG. 6 is a view showing various structures in place of the drum shown in FIG. 1, and FIG. 7 is another view showing a mechanism for holding and rotating the plate 12 shown in FIG. It is a figure which shows the example of. 1 ... Drum, 2 ... Support member 3 ... Shaft, 4 ... Arm 5 ... Arm support stand, 6 ... Base stand 7,8 ... Gear, 9 ... Controller 11 ... Well, 12 ... Plate 13 ... Liquid (second liquid) 14 ... Plasma fluid (first liquid) 30 ... Protein A
───────────────────────────────────────────────────── フロントページの続き (56)参考文献 特開 昭63−252252(JP,A) 特表 昭63−500962(JP,A) 特表 昭62−501233(JP,A) ─────────────────────────────────────────────────── ─── Continuation of the front page (56) Reference JP-A-63-252252 (JP, A) Special table Sho-63-500962 (JP, A) Special table Sho-62-501233 (JP, A)
Claims (2)
的に結合する物質を固着し、この容器に、抗原と抗体が
結合して成る抗原抗体複合体をその表面に有する細胞を
含む第1の液体よりも高比重の第2の液体を収容してこ
の第2の液体に前記物質が浸漬された状態とし、次にこ
の第2の液体の上に前記第1の液体を収容し、前記内壁
のうち前記一部が最も回転中心から遠い位置となる状態
で前記容器を回転運動させ、前記細胞を前記物質に結合
させて固相化した後、洗浄して同定する複雑抗原抗体反
応系における細胞同定法。1. A container containing a cell having an antigen-antibody complex formed by binding an antigen and an antibody on the surface of which a substance that specifically binds to an immunoglobulin is fixed to a part of the inner wall of the container. A second liquid having a higher specific gravity than that of the first liquid and containing the substance in the second liquid, and then containing the first liquid on the second liquid; A complex antigen-antibody reaction system in which the container is rotationally moved in a state in which the part of the inner wall is farthest from the center of rotation, the cells are bound to the substance to be solid-phased, and then washed to be identified. Cell identification method in.
免疫グロブリンと特異的に結合する物質と、抗原と抗体
が結合して成る抗原抗体複合体を表面に有する細胞を含
む第1の液体よりも高比重であって前記物質を浸漬する
ように前記容器に収容された第2の液体と、前記内壁の
うち前記一部が最も回転中心から遠い位置となる状態で
前記容器を回転運動させる容器回転手段とを具備する複
雑抗原抗体反応系における細胞同定法に使用される細胞
固相化装置。2. A first container comprising a container, a substance fixed to a part of an inner wall of the container and specifically binding to an immunoglobulin, and a cell having an antigen-antibody complex formed by binding an antigen and an antibody on the surface thereof. The second liquid having a higher specific gravity than the liquid and stored in the container so as to immerse the substance, and the container is rotated in a state where the part of the inner wall is farthest from the rotation center. A cell immobilization device used for a cell identification method in a complex antigen-antibody reaction system, comprising a container rotating means for moving.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1075769A JPH0731196B2 (en) | 1989-03-28 | 1989-03-28 | Cell identification method in complex antigen-antibody reaction system and cell immobilization apparatus used in this method |
| US07/492,167 US5264340A (en) | 1989-03-28 | 1990-03-13 | Cell surface antigen determination method for determining an immunocyte in a complexed antigen-antibody reaction system |
| EP90105239A EP0389929B1 (en) | 1989-03-28 | 1990-03-20 | Method for determining cell surface antigen in complexed antigen-antibody reaction system and immunocyte-fixation apparatus used in said method |
| DE69016236T DE69016236T2 (en) | 1989-03-28 | 1990-03-20 | Method for the determination of cell surface antigen by a complex antigen-antibody reaction system and apparatus used in this method for the fixation of immunocytes. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1075769A JPH0731196B2 (en) | 1989-03-28 | 1989-03-28 | Cell identification method in complex antigen-antibody reaction system and cell immobilization apparatus used in this method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH02253161A JPH02253161A (en) | 1990-10-11 |
| JPH0731196B2 true JPH0731196B2 (en) | 1995-04-10 |
Family
ID=13585747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1075769A Expired - Lifetime JPH0731196B2 (en) | 1989-03-28 | 1989-03-28 | Cell identification method in complex antigen-antibody reaction system and cell immobilization apparatus used in this method |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US5264340A (en) |
| EP (1) | EP0389929B1 (en) |
| JP (1) | JPH0731196B2 (en) |
| DE (1) | DE69016236T2 (en) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5861469A (en) * | 1981-10-08 | 1983-04-12 | Mochida Pharmaceut Co Ltd | Inclined rotating device for reactor |
| FI841023A0 (en) * | 1984-03-14 | 1984-03-14 | Labsystems Oy | FOERFARANDE FOER UTFOERING AV IMMUNOBESTAEMNINGAR |
| FR2571498B1 (en) * | 1984-10-04 | 1988-04-08 | Immunotech Sa | METHOD FOR SEPARATING CELLS USING LOW DENSITY ANTIBODIES AND BALLS |
| DD235337A1 (en) * | 1985-03-08 | 1986-04-30 | Akad Wissenschaften Ddr | METHOD AND DEVICE FOR IMPLEMENTING IMMUNOLOGICAL PROVISIONS |
| US4721681A (en) * | 1985-05-14 | 1988-01-26 | Fisher Scientific Company | Immunoassay in centrifugal field with complementary particles of differing specific gravities |
| FI853523A0 (en) * | 1985-09-13 | 1985-09-13 | Labsystems Oy | FOERFARANDE FOER UTFOERING AV IMMUNOBESTAEMNINGAR MED HJAELP AV ENZYMSTAEMPEL. |
| EP0358758A1 (en) * | 1987-04-09 | 1990-03-21 | Terumo Kabushiki Kaisha | B lymphocyte separating material and body fluid clarifying material |
| JPH0623758B2 (en) * | 1987-04-09 | 1994-03-30 | テルモ株式会社 | B lymphocyte separation material, separation method and separator |
-
1989
- 1989-03-28 JP JP1075769A patent/JPH0731196B2/en not_active Expired - Lifetime
-
1990
- 1990-03-13 US US07/492,167 patent/US5264340A/en not_active Expired - Fee Related
- 1990-03-20 EP EP90105239A patent/EP0389929B1/en not_active Expired - Lifetime
- 1990-03-20 DE DE69016236T patent/DE69016236T2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US5264340A (en) | 1993-11-23 |
| JPH02253161A (en) | 1990-10-11 |
| DE69016236D1 (en) | 1995-03-09 |
| EP0389929B1 (en) | 1995-01-25 |
| DE69016236T2 (en) | 1995-05-24 |
| EP0389929A3 (en) | 1991-07-24 |
| EP0389929A2 (en) | 1990-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0528708B1 (en) | Method and magnetic device for solid phase immunological assay | |
| US20070141725A1 (en) | Immunological Assay System and Method | |
| JP4884361B2 (en) | Chemical reaction equipment using microbeads | |
| KR101398764B1 (en) | Device for detecting analytes by moving the particle and method using the same | |
| US5770086A (en) | Methods and apparatus using hydrogels | |
| US5084240A (en) | Centrifuge vessel for automated solid-phase immunoassay | |
| US20060133954A1 (en) | Resuspension of magnetizable particles | |
| CN101377518B (en) | Automatic analyzer | |
| US5244635A (en) | Centrifuge vessel with coaxial waste chamber having cap to prevent waste fluid transfer from the chamber into the vessel | |
| JP2019507887A (en) | Centrifugation detection method and apparatus | |
| WO2018177445A1 (en) | Centrifugation immunochromatography detection method and apparatus | |
| SE454466B (en) | IMMUNOLOGICAL PROCEDURE AND APPARATUS FOR REPOSITION OF SOLID AND LIQUID PHASES THROUGH THE REACTION GERLE ROTATES UNDER TILT | |
| CA2530717C (en) | Immunological assay system and method | |
| JPH0731196B2 (en) | Cell identification method in complex antigen-antibody reaction system and cell immobilization apparatus used in this method | |
| JPH01267459A (en) | Particle flocculation determining container | |
| JP2007114162A (en) | Assay method, sensor device for implementing the same, and measuring device for sensor device | |
| JPH0447266A (en) | Agitating system for reagent vessel | |
| JPH03191864A (en) | Method and apparatus for measuring indirect agglutination immunity | |
| JPH0727680A (en) | Blood cell separation method | |
| JPH06148188A (en) | Immunological reinspecting method | |
| US20140057290A1 (en) | Method for performing a biochemical analysis, especially in outer space | |
| WO2011045022A1 (en) | Assay and device therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313115 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| EXPY | Cancellation because of completion of term |